HEN3:XETRHenkel AG & Co. KGaA Pref Analysis
Data as of 2026-03-13 - not real-time
€70.08
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Henkel (HEN3) is trading at €70.08, comfortably above its 30‑day support of €68.94 but still below the 20‑day SMA of €78.70 and the 50‑day SMA of €75.97, indicating a short‑term price lag. The RSI of 26.2 places the stock in oversold territory, while the MACD remains bearish, suggesting a potential near‑term rebound amid a broader bullish trend direction. Valuation metrics show a forward P/E of 11.9 and a trailing P/E of 14.0, with the DCF‑derived fair value at €46.79, implying the market is pricing a modest premium but still within a reasonable range given the target median price of €76.5. The dividend yield of 2.91% and a payout ratio of 40.8% are supported by strong operating cash flow of €2.54 bn and a free cash flow conversion of roughly €1.47 bn, underscoring dividend sustainability.
The company’s defensive consumer‑goods positioning, low beta (≈0.12) and modest 30‑day volatility of 27.6% mitigate market risk, though regulatory exposure in chemicals and a global geographic footprint introduce medium‑level regulatory and geographic risks. With a solid gross margin of ~51% and operating margin near 12%, earnings remain resilient despite a 6.3% revenue contraction, and the balance sheet shows manageable debt levels (debt‑to‑equity ~18%). Overall, the stock presents a fair‑valued, dividend‑rich opportunity with upside potential of roughly 12% while maintaining a defensive risk profile.
The company’s defensive consumer‑goods positioning, low beta (≈0.12) and modest 30‑day volatility of 27.6% mitigate market risk, though regulatory exposure in chemicals and a global geographic footprint introduce medium‑level regulatory and geographic risks. With a solid gross margin of ~51% and operating margin near 12%, earnings remain resilient despite a 6.3% revenue contraction, and the balance sheet shows manageable debt levels (debt‑to‑equity ~18%). Overall, the stock presents a fair‑valued, dividend‑rich opportunity with upside potential of roughly 12% while maintaining a defensive risk profile.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- RSI in oversold region suggesting price rebound
- Price just above key support level with increasing volume
- Defensive sector and low beta reducing short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Stable cash generation supporting dividend payout
- Forward P/E below 12 indicating reasonable valuation
- Broad geographic diversification balancing growth and risk
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Consistent dividend yield with sustainable payout ratio
- Defensive consumer‑goods exposure in a low‑growth environment
- Low beta and modest volatility reinforcing defensive profile
Key Metrics & Analysis
Financial Health
Revenue Growth-6.30%
Profit Margin9.93%
P/E Ratio14.0
ROE9.71%
ROA5.09%
Debt/Equity18.02
P/B Ratio1.4
Op. Cash Flow€2.5B
Free Cash Flow€1.5B
Technical Analysis
TrendBullish
RSI26.2
Support€68.94
Resistance€84.20
MA 20€78.70
MA 50€75.97
MA 200€71.50
MACDBearish
VolumeIncreasing
Fear & Greed Index73.32
Valuation
Fair Value€46.79
Target Price€78.34
Upside/Downside11.78%
GradeFair
TypeValue
Dividend Yield2.91%
Risk Assessment
Beta0.12
Volatility27.61%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.